Lowering triglycerides to modify cardiovascular risk: will icosapent deliver? - Wikidata - wikimedia - TriplyDB

Lowering triglycerides to modify cardiovascular risk: will icosapent deliver?

Lowering triglycerides to modify cardiovascular risk: will icosapent deliver?

http://www.wikidata.org/entity/Q35230819

about

A comparative study between Wuweizi seed and its post-ethanol extraction residue in normal and hypercholesterolemic mice.Combined therapy with metformin and insulin attenuates systemic and hepatic alterations in a model of high-fat diet-/streptozotocin-induced diabetes.

P2860

Q30387831-4978E5E3-85DB-419D-9C79-112168484A20 Q46522590-B574C2A0-6644-4791-B027-9533D4603008

P2860

Lowering triglycerides to modify cardiovascular risk: will icosapent deliver?

http://www.wikidata.org/entity/Q35230819

description

2015 nî lūn-bûn

@nan

2015 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի մարտին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

Lowering triglycerides to modify cardiovascular risk: will icosapent deliver?

@ast

Lowering triglycerides to modify cardiovascular risk: will icosapent deliver?

@en

type

label

Lowering triglycerides to modify cardiovascular risk: will icosapent deliver?

@ast

Lowering triglycerides to modify cardiovascular risk: will icosapent deliver?

@en

prefLabel

Lowering triglycerides to modify cardiovascular risk: will icosapent deliver?

@ast

Lowering triglycerides to modify cardiovascular risk: will icosapent deliver?

@en

P1433

Q35230819-C5942DE3-36A7-4F6B-8B1F-B6146484A280

P1476

Q35230819-B4A41010-0802-4AF7-A516-F7C87F947FDB

P2093

Q35230819-318D4B6C-6FB7-48F1-AA53-54291D3F2685

Q35230819-A3EE7E9F-B07E-496E-9B29-1900A6FA967E

P275

Q35230819-32A8A81F-50C4-49FF-924B-6AF13705EE30

P2860

Q35230819-0EA4562E-0743-4C8A-BF0D-00DDC735E09F

Q35230819-0F40F6D6-4001-4FB5-A932-96B283F02CA4

Q35230819-1303589C-D701-4163-BCBF-91014B970E2B

Q35230819-1964ED7E-2703-4D67-A5E5-A7D0CE6058F0

Q35230819-2154284B-1CFB-40E0-9B9D-806F6483A9CA

Q35230819-22E1568F-89DB-419A-852D-70BF323A8D70

Q35230819-29834A22-22E2-4F8E-B8C6-24DBB0FECA4C

Q35230819-2EF559D6-E05A-40CB-9DEA-F9A471D3F814

Q35230819-3001F31B-99D2-471B-886B-CD321C778880

Q35230819-3068D1E2-65F7-4EDF-8F35-B1F4E6110125

P304

Q35230819-107E9040-CDB8-4036-9870-BF8502D544A4

P31

Q35230819-B890367E-980B-48A3-915F-A9B7C944D613

Q35230819-C4C6EEF2-579D-4934-97A8-9DDA05E94414

P356

Q35230819-17B644E9-EAB9-494C-BBF8-E364CA04B141

P407

Q35230819-7A5782BC-637D-4872-8EA6-B8668ECE8340

P478

Q35230819-35C7D287-50FD-4329-B22E-DDEAFCED2331

P50

Q35230819-3FF58CEB-83CA-46F7-A604-A06DCDB3FC0F

Q35230819-D70C1881-7325-4EF4-A755-A200E24DE979

P5008

Q35230819-E512CD13-89AB-4F89-9513-EBE0D3B31723

P577

Q35230819-8EB9C109-6F2E-4921-A452-F564349B4F7F

P698

Q35230819-73EDEEEA-6D0D-4648-B13E-0D8F9599C768

P921

Q35230819-018E8A68-57EE-4CA4-A5EB-A863CDE369F2

Q35230819-25E29468-53D6-4591-A6C2-4C4AA7214171

Q35230819-28CC81A1-7F10-40F2-9301-EDA9980B6CA6

Q35230819-2BD8DBC1-904E-4646-AF66-E963FD99D331

Q35230819-558D7286-1E8C-4B29-9823-EEB959C14A3E

Q35230819-B468C3EB-D99D-4A6F-85C3-531764306754

P932

Q35230819-59541803-E88F-4568-8155-D63E1274C724

P356

P1433

Vascular Health and Risk Management

P1476

Lowering triglycerides to modify cardiovascular risk: will icosapent deliver?

@en

P2093

Daniel J Scherer

http://www.w3.org/2001/XMLSchema#string

Stephen J Nicholls

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution-NonCommercial

P2860

Modulation of lipoprotein lipase activity by apolipoproteins. Effect of apolipoprotein C-III

Mechanism of action of fibrates on lipid and lipoprotein metabolism

Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy

Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials

Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group

Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial

Unsaturated fatty acids down-regulate srebp isoforms 1a and 1c by two mechanisms in HEK-293 cells.

Atherogenic role of elevated CE transfer from HDL to VLDL(1) and dense LDL in type 2 diabetes : impact of the degree of triglyceridemia.

Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial.

Weight loss with a low-carbohydrate, Mediterranean, or low-fat diet.

P304

203-209

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2147/VHRM.S40134

http://www.w3.org/2001/XMLSchema#string

P407

P478

11

http://www.w3.org/2001/XMLSchema#string

P50

Stephen Nicholls

Daniel J Scherer

P5008

P577

2015-03-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25848301

http://www.w3.org/2001/XMLSchema#string

P921

hypertriglyceridemia

mechanism of action

cardiovascular disease

P932

4378876

http://www.w3.org/2001/XMLSchema#string